Plasminogen Activator Inhibitor Antigen 1 (PAI-1), Plasma
PAI-1 is a 43 kDa single-chain glycoprotein and a serine protease inhibitor produced primarily by endothelial cells and hepatocytes. It is also stored in platelet α-granules and released during vascular injury. Circulating PAI-1 binds vitronectin, which stabilizes its active form.
PAI-1 is the principal inhibitor of tissue-type plasminogen activator (tPA) and urokinase (uPA), and therefore plays a central role in regulating fibrinolysis. Although synthesized in an active form, PAI-1 is functionally unstable, with an in vivo half-life of approximately 2 hours.
PAI-1 exists in four conformations:
- Active (inhibitory)
- Latent (nonreactive)
- Substrate (cleavable, non-inhibitory)
- Cleaved/inert
Elevated PAI-1 levels impair fibrinolysis and are associated with thrombotic risk, including veno-occlusive disease (VOD) following bone marrow transplantation (BMT). PAI-1 antigen has been identified as an independent diagnostic and severity marker of VOD and may help distinguish VOD from other causes of post-transplant hyperbilirubinemia.
Increased PAI-1 levels are also observed in malignancy, liver disease, postoperative states, sepsis, pregnancy (2nd–3rd trimester), obesity, and coronary heart disease.
Reduced or absent active PAI-1 (congenital or acquired) is associated with clinically significant bleeding, including hemarthroses, hematomas, menorrhagia, easy bruising, and postoperative hemorrhage.
- Evaluation of thrombotic risk
- Evaluation of deep venous thromboembolism, including women taking oral contraceptives or hormone replacement
- Evaluation of coronary artery disease and/or stroke
- Evaluation of recurrent miscarriages
- Evaluation of pregnancy complications
- Evaluation of meningococcal sepsis
Positive results are considered if homozygous (4G/4G) or heterozygous (4G/5G or 5G/4G) are detected. The presence of these variations could indicate increase risk in:
- Deep venous thrombosis
- Pulmonary embolism
- Patients with history of recurrent miscarriages
- Venous thrombosis
- Stroke
- Heart attack and stroke
- Preeclampsia
- Recurrent miscarriages
- Pregnancy complications and termination (spontaneous abortion)
- Cancer
Decreased in:
- Hyperfibrinolysis resulting from PAI-1 deficiency; this is a rare bleeding disorder
3.1-72.0 ng/mL
Enzyme-Linked Immunosorbent Assay (ELISA).
Platelet-poor plasma, Light-blue top (3.2% sodium citrate).
Separate plasma within 4 hour and freeze.
Stability
- Ambient: not acceptable
- Refrigerated: not acceptable
- Frozen: up to 30 days
- Thromb Haemost. 1995 Jul;74(1):71-6. [PMID: 8578529]
- Thromb Haemost. 1998 Dec;80(6):956-60. [PMID: 9869167]
- Br J Haematol. 2000 Oct;111(1):122-8. [PMID: 11091191]
- Clin Appl Thromb Hemost. 2003 Oct;9(4):299-307. [PMID: 14653439]
- Thromb Haemost. 1997 Apr;77(4):730-4. [PMID: 9134651]
- Thromb Res. 2008;122(6):736-42. [PMID: 17949795]